MigVax

Vaccine for Viruses in Humans

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in March 2020, MigVax operates with 1–10 employees. The company has secured $21.3M in total capital across 4 funding rounds from 2 investors, with OurCrowd leading an April 2020 round. In June 2022, MigVax signed an agreement with Catalent to develop an orally disintegrating freeze-dried tablet vaccine against COVID-19.

Business overview

MigVax is a health tech and life sciences company focused on the development and commercialization of vaccines for human viruses. The company's core technology utilizes a sub-unit vaccine approach based on a chimeric protein that presents viral proteins to the immune system via the oropharynx. This method aims to generate mucosal, blood-based, and cell-mediated immunity. MigVax initially applied this technology to develop a COVID-19 vaccine, leveraging prior success in creating a vaccine against avian coronavirus. The company operates within the pharmaceuticals sector, targeting drug development and vaccine markets.

Strategic signal

In June 2022, MigVax partnered with Catalent to develop an orally disintegrating freeze-dried tablet vaccine against COVID-19. This collaboration signals a strategic move towards innovative drug delivery methods and potentially broader market accessibility for their vaccine technology, indicating a focus on advanced pharmaceutical formulation and commercialization pathways for investors.

Company Intelligence Q&A

What is MigVax's primary focus in vaccine development?
MigVax focuses on developing vaccines for human viruses, initially concentrating on COVID-19. Their approach utilizes a sub-unit vaccine based on a chimeric protein to elicit mucosal, blood-based, and cell-mediated immunity.
When was MigVax founded and what is its employee count?
MigVax was founded in March 2020 and currently operates with 1–10 employees.
Which company did MigVax partner with for vaccine development in June 2022?
In June 2022, MigVax signed an agreement with Catalent to develop an orally disintegrating freeze-dried tablet vaccine against COVID-19.
What was a significant leadership change at MigVax in May 2022?
In May 2022, MigVax appointed Ran Amir as its new CEO.
Which investors participated in MigVax's April 2020 funding round?
In April 2020, MigVax secured funding from investors including OurCrowd and Happiness Capital.

External links